GSA Capital Partners LLP Sells 109,045 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

GSA Capital Partners LLP lowered its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 75.5% during the third quarter, HoldingsChannel reports. The fund owned 35,313 shares of the biotechnology company’s stock after selling 109,045 shares during the quarter. GSA Capital Partners LLP’s holdings in ADMA Biologics were worth $706,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Hollencrest Capital Management acquired a new stake in ADMA Biologics in the 3rd quarter worth $30,000. Quest Partners LLC bought a new stake in shares of ADMA Biologics in the second quarter valued at about $29,000. EntryPoint Capital LLC bought a new stake in shares of ADMA Biologics in the first quarter valued at about $31,000. USA Financial Formulas grew its position in ADMA Biologics by 8.6% during the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock worth $136,000 after buying an additional 539 shares in the last quarter. Finally, CWM LLC increased its stake in ADMA Biologics by 114.2% during the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after acquiring an additional 4,367 shares during the period. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Trading Down 5.7 %

ADMA opened at $19.04 on Monday. The firm has a 50 day simple moving average of $18.54 and a 200 day simple moving average of $14.40. The company has a market cap of $4.50 billion, a price-to-earnings ratio of 68.00 and a beta of 0.64. ADMA Biologics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter last year, the firm earned $0.01 EPS. On average, sell-side analysts anticipate that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have commented on ADMA shares. HC Wainwright raised their price objective on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, Raymond James boosted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th.

Insiders Place Their Bets

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $16.90, for a total transaction of $408,135.00. Following the sale, the chief operating officer now directly owns 449,088 shares of the company’s stock, valued at $7,589,587.20. The trade was a 5.10 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now owns 2,059,726 shares in the company, valued at $36,436,552.94. The trade was a 10.31 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 466,900 shares of company stock worth $8,224,121. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.